Patents Assigned to GeneStem Co., Ltd.
  • PARTNER OF SLD FIVE 1 (PSF1)-DERIVED PEPTIDE
    Publication number: 20170173133
    Abstract: Embodiments of the present invention provide a PSF1-derived peptide useful for a specific immunotherapy for cancer patients. The present invention provides a PSF1-derived peptide which can induce a CTL and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the embodiments of the present invention.
    Type: Application
    Filed: January 23, 2017
    Publication date: June 22, 2017
    Applicants: GeneStem Co., Ltd., Osaka Urban Industry Promotion Center
    Inventors: Hidekazu TANAKA, Motofumi IGUCHI, Mari YOKOYAMA
  • PSF1-derived peptide
    Patent number: 9683016
    Abstract: PSF 1-derived peptides and pharmaceutical compositions of the peptides are described for immunotherapy of cancer patients. The peptides and pharmaceutical compositions containing these peptides induce a CTL response for treating or preventing cancer.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: June 20, 2017
    Assignees: GENESTEM CO., LTD., OSAKA URBAN INDUSTRY PROMOTION CENTER
    Inventors: Hidekazu Tanaka, Motofumi Iguchi, Mari Yokoyama
  • PSF1-DERIVED PEPTIDE
    Publication number: 20150218216
    Abstract: The purpose of the present invention is to provide a PSF1-derived peptide useful for a specific immunotherapy for cancer patients. The present invention provides: a PSF1-derived peptide which can induce a CTL; and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention.
    Type: Application
    Filed: August 29, 2013
    Publication date: August 6, 2015
    Applicant: GeneStem Co., Ltd.
    Inventors: Hidekazu Tanaka, Motofumi Iguchi, Mari Yokoyama